



## **OFFICE OF GENERIC DRUGS**

Office of Generic Drugs (HFD-600)  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Metro Park North VII  
7620 Standish Place  
Rockville, MD 20855  
Fax: 240-276-9327

### **FAX TRANSMISSION COVER SHEET**

APPLICANT: Gordon Jonston Regulatory  
Consultants LLC

TEL: 240-401-7616

ATTN: Gordon Johnston

FAX: 301-570-70755

FROM: Linda Park

FDA CONTACT PHONE: (240) 276-8536

Dear Sir:

This facsimile is in reference to your abbreviated new drug application dated February 20, 2010, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Quetiapine Fumarate Tablets, 25 mg (base), 50 mg (base), 100 mg (base), 150 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base).

We are pleased to inform you that this application is **APPROVED!**

**THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.**

If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Silver Spring, MD 20993

ANDA 201504

Gordon Johnston Regulatory Consultants LLC  
U.S. Agent for: Alkem Laboratories Limited  
Attention: Gordon Johnston  
3631 Martins Dairy Circle  
Olney, MD 20832

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated February 20, 2010, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Quetiapine Fumarate Tablets, 25 mg (base), 50 mg (base), 100 mg (base), 150 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base).

Reference is also made to your amendments dated June 9, and October 12, 2010; June 2, July 18, July 19, September 20, October 4, and October 29, 2011; and February 14, February 16, February 27, March 27, May 11, September 13, and October 4, 2012.

We note that one of the drug products upon which you have based this ANDA, AstraZeneca L.P.'s Seroquel Tablets 150 mg (base), is no longer being marketed in the U.S. and is currently listed in the discontinued section of the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, the "Orange Book". Reference is made to the Federal Register notice dated January 25, 2008 (Volume 73, No. 17) in which the agency announced its determination that Seroquel Tablets 150 mg (base) were not withdrawn from sale for reasons of safety or effectiveness. This determination allows the agency to approve ANDAs for the discontinued drug product.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has

FEB. 12. 2013 2:00PM

CDER/OGD/CHEM1

NO. 472

P. 3

determined your Quetiapine Fumarate Tablets, 25 mg (base), 50 mg (base), 100 mg (base), 150 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base) to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug product (RLD), Seroquel Tablets 25 mg (base), 50 mg (base), 100 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base), of AstraZeneca LP. Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Amundson Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information

on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

*{See appended electronic signature page}*

Gregory P. Geba, M.D., M.P.H.  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
ROBERT L WEST

02/12/2013

Deputy Director, Office of Generic Drugs, for  
Gregory P. Geba, M.D., M.P.H.